Serum neuron specific enolase may be a marker to predict the severity and outcome of cerebral venous thrombosis. 2018

Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
Departments of Neurology, Neurosurgery, Ophthalmology and Emergency, Xuanwu Hospital, Capital Medical University, Beijing Institute for Brain Disorders, Beijing, 100053, China.

The objective is to explore the effective of baseline serum neuron specific enolase (NSE) on predicting the severity and outcome in patients with cerebral venous thrombosis (CVT). A total of 156 patients confirmed as CVT in Xuanwu Hospital were enrolled in this retrospective study from March 2011 through September 2016. The severity was evaluated with the National Institutes of Health Stroke Score (NIHSS), intracranial pressure (ICP), and CVT-related complications; the outcome was evaluated by modified Rankin Scale (mRS); the relationship between baseline serum NSE and mRS was analyzed with receiver operating characteristic curve (ROC), logistic regression analysis, and Kaplan-Meier curves. Baseline level of serum NSE was positively associated with baseline NIHSS (r = 0.322, p < 0.001). Among which, patients with high level of serum NSE were also noticed with cerebral venous infarction (p < 0.001), intracranial hemorrhage (p < 0.001), seizure (p = 0.035). Meanwhile, patients in NSE ≥ 15.05 ng/mL group vs. NSE < 15.05 ng/mL group had large mRS scores (≥ 3) at discharge (adjusted OR: 5.40, 95% CI 1.27-22.91; p = 0.022) and higher percentage of mRS scores ≥ 3 during 40 months of outpatient follow-up (log-rank p < 0.001). Baseline level of serum NSE is positively associated with the severity of CVT. Presumably NSE may be a potential predictor for the clinical outcome of CVT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
September 2004, Brain & development,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
November 1989, Journal of the National Cancer Institute,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
February 1992, British journal of cancer,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
January 1987, Lancet (London, England),
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
January 2009, The neurologist,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
January 1996, International urology and nephrology,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
January 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
September 1987, Cancer,
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
October 1993, Lancet (London, England),
Yanyu Hu, and Ran Meng, and Xuxiang Zhang, and Linlin Guo, and Sijie Li, and Yan Wu, and Jiangang Duan, and Yuchuan Ding, and Xunming Ji
January 1993, European urology,
Copied contents to your clipboard!